Not yet recruitingPhase 2NCT06768294
Baricitinib in CPPD - the BAPTIST Study
Studying Familial calcium pyrophosphate deposition
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
- Principal Investigator
- Georgios Filippou, Assistant ProfessorIRCCS Galeazzi - Sant'Ambrogio Hospital
- Intervention
- Baricitinib 4 MG Oral Tablet(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 55 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- IRCCS Galeazzi - Sant Ambrogio Hospital, Milan, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06768294 on ClinicalTrials.gov